Stocks To Watch: Bristol-Myers Squibb Company (BMY), Gilead Sciences Inc. (GILD), Hilton Worldwide Holdings Inc. (HLT)

Bristol-Myers Squibb Company (BMY) traded within a range of $55.3 to $56.11 after opening the day at $55.69. The company has seen its stock decrease in value by -17.16% so far this year. The stock was up close to 0.29% on light volume in last trading session and closed at $55.96 per share. After the recent gain, the stock is currently holding -26.93% below its 52 week high of $77.12 and 14.13% above its 12-month low of $49.03. The shares are down by over 0% in the last three months, and the RSI indicator value of 54.57 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that targets and blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung cancer, renal cell cancer, and melanoma; Sprycel, a multi-targeted tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with metastatic melanoma; Abilify, an antipsychotic agent for adult patients with schizophrenia, bipolar mania disorder, and major depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor that is in regulatory review for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. The company was founded in 1887 and is headquartered in New York, New York.

Gilead Sciences Inc. (GILD) continued its downward trend with the stock declining -0.58% or $-0.42 to close the day at $72.42 on light trading volume of 9.22M shares, compared to its three month average trading volume of 9.58M. The Foster City California 94404 based company has been underperforming the biotechnology group over the past 52 weeks, with the stock losing -27.07%, compared to the industry which has dropped -4.15% over the same period. With RSI of 36.59, the stock should still continue to rise and get closer to its one year target estimate of $95.74, making it a hold for now.

Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company’s products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.

Hilton Worldwide Holdings Inc. (HLT) gained $0.05 to close the day at a new closing price of $25.26, a 0.2% increase in value from its previous closing price that moved the stock 58.27% above its 52 week low of $16.16. A total of 9.19M shares exchanged hands during the day compared with its three month average trading volume of 7.61M. The stock, which fluctuated between $25.11 and $25.37 during the day, currently situated -0.75% below its 52 week high. The stock is up by 13.62% in the past one month and up by 6.73% over the past three months. With a one year target estimate of $25.95 and RSI of 71.59, the stock still has upside potential, making it a sell for now.

Hilton Worldwide Holdings Inc., a hospitality company, owns, leases, manages, develops, and franchises hotels, resorts, and timeshare properties worldwide. The company operates through three segments: Ownership, Management and Franchise, and Timeshare. It also licenses its brands to franchisees; provides hotel management services for third parties; and markets and sells timeshare interests owned by Hilton and third parties. In addition, the company provides consumer financing, which includes interest income generated from the origination of consumer loans to finance their purchase of timeshare intervals. It operates hotels under the Waldorf Astoria Hotels & Resorts, Conrad Hotels & Resorts, Canopy by Hilton, Hilton Hotels & Resorts, Curio – A Collection by Hilton, DoubleTree by Hilton, Embassy Suites by Hilton, Hilton Garden Inn, Hampton by Hilton, Tru by Hilton, Homewood Suites by Hilton, Home2 Suites by Hilton, Hilton Grand Vacations, and Hampton Inn brands. As of November 10, 2016, the company had approximately 4,800 managed, franchised, owned, and leased hotels, resorts, and timeshare properties comprising 789,000 rooms in 104 countries and territories. Hilton Worldwide Holdings Inc. was founded in 1919 and is headquartered in McLean, Virginia.

 

Stocks in the Spotlight: Gilead Sciences Inc. (GILD), AbbVie Inc. (ABBV), Johnson & Johnson (JNJ)

Gilead Sciences Inc. (GILD) had a light trading with around 8.25M shares changing hands compared to its three month average trading volume of 9.64M. The stock traded at the price of $72.84 with -1.17% change on the day. The company is currently trading 2.03% above its 52 week low of $71.39 and -30.74% below its 52 week high of $108.31. Both the RSI indicator and target price of 38.48 and $95.74 respectively, lead us to believe that it should be put on hold over the coming weeks.

Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company’s products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.

AbbVie Inc. (ABBV) continued its downward trend with the stock declining -2.7% or $-1.64 to close the day at $59.16 on active trading volume of 8.23M shares, compared to its three month average trading volume of 7.36M. The North Chicago Illinois 60064 based company has been outperforming the drug manufacturers – major group over the past 52 weeks, with the stock gaining 6.46%, compared to the industry which has dropped -3.51% over the same period. With RSI of 44.57, the stock should still continue to rise and get closer to its one year target estimate of $70, making it a hold for now.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for adults with genotype 1 chronic hepatitis, including those with compensated cirrhosis. It also provides Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent respiratory syncytial virus infection in high risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and endometriosis and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson’s disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, and Niaspan to treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has strategic collaboration with C2N Diagnostics; Calico Life Sciences LLC; Infinity Pharmaceuticals, Inc.; Ablynx NV; Galapagos NV; and Alvine Pharmaceuticals, Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.

Johnson & Johnson (JNJ) shares were up in last trading by 0.07% to $111.38. It experienced higher than average volume on day. The stock decreased in value by almost -1.49% over the past week and fell -2.77% in the past month. It is currently trading -3.86% below its 50 day moving average and -2.38% below its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -10.45% decrease in value from its one year high of $126.07. The RSI indicator value of 34.15, lead us to believe that it is a hold for now.

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates through three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON’S brand name; oral care products under the LISTERINE brand name; skin care products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON’S Adult, LE PETITE MARSEILLAIS, LUBRIDERM, NEUTROGENA, and RoC brand names; women’s health products, such as sanitary pads under the STAYFREE and CAREFREE, and o.b. tampon brand names; wound care products, including adhesive bandages under the BAND-AID brand name and first aid products under the NEOSPORIN brand name. This segment also provides over-the-counter medicines, including acetaminophen products under the TYLENOL brand name; cold, flu, and allergy products under the SUDAFED brand name; allergy products under the BENADRYL and ZYRTEC brand names; ibuprofen products under the MOTRIN IB brand name; and heartburn products under the PEPCID brand name. The Pharmaceutical segment provides various products in the areas of immunology, infectious diseases and vaccines, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment offers orthopaedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular disease; sterilization and disinfection products to reduce surgical infection; blood glucose monitoring and insulin delivery products; and disposable contact lenses. The company offers its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use, as well as for use in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.

 

Stocks Highlights: Gilead Sciences (GILD), Rite Aid (RAD), Hilton Worldwide (HLT)

Rite Aid Corporation (RAD) had a light trading with around 10.66M shares changing hands compared to its three month average trading volume of 16.91M. The stock traded between $7.94 and $8.05 before closing at the price of $7.96 with -1.12% change on the day. The Camp Hill Pennsylvania 17011 based company is currently trading 25.75% above its 52 week low of $6.33 and -4.1% below its 52 week high of $8.3. Both the RSI indicator and target price of 63.45 and $8.69 respectively, lead us to believe that it should be put on hold over the coming weeks.

Rite Aid Corporation, through its subsidiaries, operates a chain of retail drugstores in the United States. The company operates through two segments, Retail Pharmacy and Pharmacy Services. The Retail Pharmacy Segment sells prescription drugs; and a range of other merchandises, such as over-the-counter medications, health and beauty aids, personal care items, cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, and other everyday and convenience products. It also operates retail clinics that provide treatment for common conditions; and a range of preventive services, including screenings, medical tests, immunizations, and basic physical exams. In addition, this segment provides health coaching, shared decision making tools, and health care analytics, including health coaching for medical decisions, chronic conditions, and wellness; population analytic solutions; and consulting services. The Pharmacy Services Segment provides pharmacy benefit management (PBM) services and a range of pharmacy-related services. It also offers integrated mail-order and specialty pharmacy services; and performs prescription adjudication services for other PBMs. Rite Aid Corporation has a strategic alliance with GNC. As of February 27, 2016, the company operated approximately 4,561 stores in 31 states of the United States and in the District of Columbia. Rite Aid Corporation was founded in 1927 and is headquartered in Camp Hill, Pennsylvania.

Hilton Worldwide Holdings Inc. (HLT) managed to rebound with the stock climbing 1.05% or $0.26 to close the day at $25.07 on light trading volume of 10.63M shares, compared to its three month average trading volume of 7.43M. The McLean Virginia 22102 based company has been outperforming the lodging group over the past 52 weeks, with the stock gaining 7.61%, compared to the industry which has advanced 5.21% over the same period. With RSI of 69.41, the stock should still continue to rise and get closer to its one year target estimate of $25.76, making it a hold for now.

Hilton Worldwide Holdings Inc., a hospitality company, owns, leases, manages, develops, and franchises hotels, resorts, and timeshare properties worldwide. The company operates through three segments: Ownership, Management and Franchise, and Timeshare. It also licenses its brands to franchisees; provides hotel management services for third parties; and markets and sells timeshare interests owned by Hilton and third parties. In addition, the company provides consumer financing, which includes interest income generated from the origination of consumer loans to finance their purchase of timeshare intervals. It operates hotels under the Waldorf Astoria Hotels & Resorts, Conrad Hotels & Resorts, Canopy by Hilton, Hilton Hotels & Resorts, Curio – A Collection by Hilton, DoubleTree by Hilton, Embassy Suites by Hilton, Hilton Garden Inn, Hampton by Hilton, Tru by Hilton, Homewood Suites by Hilton, Home2 Suites by Hilton, Hilton Grand Vacations, and Hampton Inn brands. As of November 10, 2016, the company had approximately 4,800 managed, franchised, owned, and leased hotels, resorts, and timeshare properties comprising 789,000 rooms in 104 countries and territories. Hilton Worldwide Holdings Inc. was founded in 1919 and is headquartered in McLean, Virginia.

Gilead Sciences Inc. (GILD) shares were down in last trading by -1.56% to $73.7. It experienced higher than average volume on day. The stock decreased in value by almost -1.02% over the past week and grew 0.1% in the past month. It is currently trading -2.78% below its 50 day moving average and -11.23% below its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -30.53% decrease in value from its one year high of $108.31. The RSI indicator value of 41.54, lead us to believe that it is a hold for now.

Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company’s products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.

 

Equities Trend Analysis: Abbott Laboratories (ABT), Cognizant Technology Solutions Corporation (CTSH), Gilead Sciences Inc. (GILD)

Abbott Laboratories (ABT) retreated with the stock falling -0.03% or $-0.01 to close at $38.73 on light trading volume of 7.24M compared its three months average trading volume of 8.45M. The Abbott Park Illinois 60064 based company operating under the Medical Appliances & Equipment industry has been trending down for the last 52 weeks, with the shares price now -11.61% down for the period and down by -11.59% so far this year. With price target of $47.38 and a 9.6% rebound from 52-week low, Abbott Laboratories has plenty of upside potential, making it a hold with a view buy.

Abbott Laboratories manufactures and sells health care products worldwide. The company’s Established Pharmaceutical Products segment offers branded generic pharmaceuticals to treat pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière’s disease and vestibular vertigo; pain, fever, and inflammation; migraines; anti-infective clarithromycin; and influenza vaccines, as well as to regulate physiological rhythm of the colon. Its Diagnostic Products segment provides immunoassay and clinical chemistry systems; assays used to screen and/or diagnosis cancer, cardiac, drugs of abuse, fertility, infectious diseases, and therapeutic drug monitoring; hematology systems and reagents; diagnostic systems and cartridges; instruments that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents; genomic-based tests; informatics and automation solutions; and instrument used to identify infection-causing pathogens. The company’s Nutritional Products segment provides pediatric and adult nutritional products, such as prepared infant and follow-on formulas. Its Vascular Products segment offers coronary, endovascular, vessel closure, and structural heart devices to treat vascular disease. The company also provides blood and flash glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes; and medical devices for the eye, such as cataract and LASIK surgery, contact lens care, and dry eye products. It serves retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices, and government agencies. The company has strategic alliance with Fonterra. Abbott Laboratories was founded in 1888 and is headquartered in Abbott Park, Illinois.

Cognizant Technology Solutions Corporation (CTSH) had a active trading with around 7.22M shares changing hands compared to its three month average trading volume of 7.13M. The stock traded at the price of $55.63 with -2.32% change on the day. The Teaneck New Jersey 07666 based company is currently trading 22.43% above its 52 week low of $45.44 and -14.74% below its 52 week high of $65.43. Both the RSI indicator and target price of  and $63.73 respectively, lead us to believe that it could rise over the coming weeks.

Cognizant Technology Solutions Corporation provides information technology (IT), consulting, and business process services worldwide. The company operates through four segments: Financial Services, Healthcare, Manufacturing/Retail/Logistics, and Other. Its consulting and technology services include IT strategy consulting, program management consulting, operations improvement consulting, strategy consulting, and business consulting services; and application design and development, systems integration, enterprise resource planning, and customer relationship management implementation services. The company also offers enterprise information management services, such as strategic, advisory, and management consulting; enterprise data management; descriptive analytics/business intelligence; strategic corporate performance management; and packaged analytics services, as well as big data services that assist clients in managing and deriving actionable insights. In addition, it provides application testing services; and develops, licenses, implements, and supports proprietary and third-party software products, as well as offers digital technologies services. Further, the company offers outsourcing services, such as application maintenance services; IT infrastructure services; and business process services, including clinical data management, pharmacovigilance, equity research support, commercial operations, and order management. It serves various industries, including banking and insurance; healthcare and life sciences; manufacturing and logistics; retail, travel, and hospitality; consumer goods; communications; information, media, and entertainment; and technology. The company markets and sells services through its professional staff, senior management, and direct sales personnel. Cognizant Technology Solutions Corporation was founded in 1998 and is headquartered in Teaneck, New Jersey.

Gilead Sciences Inc. (GILD) saw its value increase by 0.44% as the stock gained $0.33 to finish the day at a closing price of $74.87. The stock was lighter in trading and has fluctuated between $71.39-$107.38 per share for the past year. The shares are down by -3.33% in the past three months and down by -12.51% over the past six months. It is currently trading -0.12% below its 20 day moving average and -1.34% below its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $95.74 a share over the next twelve months. The current relative strength index (RSI) reading is 46.21.The technical indicator lead us to believe there will be no major movement any time soon, hold.

Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company’s products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.

 

Stocks on the Move: Gilead Sciences Inc. (GILD), Delta Air Lines, Inc. (DAL), Johnson & Johnson (JNJ)

Gilead Sciences Inc. (GILD) failed to extend gains with the stock declining -1.19% or $-0.9 to close the day at $74.54 on light trading volume of 9.29M shares, compared to its three month average trading volume of 9.75M. The Foster City California 94404 based company has been underperforming the biotechnology group over the past 52 weeks, with the stock losing -29.53%, compared to the industry which has dropped -2.24% over the same period. With RSI of 45.52, the stock should still continue to rise and get closer to its one year target estimate of $95.74, making it a hold for now.

Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company’s products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.

Delta Air Lines, Inc. (DAL) fell -1.52% during last trading as the stock lost $-0.75 to finish the day at $48.49 with about 9.16M shares changing hands, compared to its three month average trading volume of 10.24M. The $36.31B market cap company, which fluctuated between $48.48 and $49.35 during the day, currently situated 50.25% above its 52 week low of $32.6 and -6.59% away from its one year high of $52.77. The RSI of 75.24 indicates the stock is overbought at the current levels, sell for now.

Delta Air Lines, Inc. provides scheduled air transportation for passengers and cargo in the United States and internationally. The company operates through two segments, Airline and Refinery. Its route network is centered around a system of hubs, international gateways, and airports in Amsterdam, Atlanta, Boston, Detroit, London-Heathrow, Los Angeles, Minneapolis-St. Paul, New York-LaGuardia, New York-JFK, Paris-Charles de Gaulle, Salt Lake City, Seattle, and Tokyo-Narita. The company sells its tickets through various distribution channels, including delta.com and mobile, telephone reservations, traditional brick and mortar, and online travel agencies. It also provides aircraft maintenance, repair, and overhaul services; staffing, and professional security and training services, as well as aviation solutions to third parties; vacation packages to third-party consumers; and aircraft charters, and aircraft management and programs. As of February 3, 2016, the company operated a fleet of approximately 800 aircrafts. Delta Air Lines, Inc. was founded in 1924 and is headquartered in Atlanta, Georgia.

Johnson & Johnson (JNJ) saw its value decrease by -0.88% as the stock dropped $-1 to finish the day at a closing price of $113.13. The stock was higher in trading and has fluctuated between $94.28-$126.07 per share for the past year. The shares, which traded within a range of $113.05 to $114.12 during the day, are down by -5.01% in the past three months and up by 1.76% over the past six months. It is currently trading -1.96% below its 20 day moving average and -2.59% below its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $126.32 a share over the next twelve months. The current relative strength index (RSI) reading is 40.97. The technical indicator lead us to believe there will be no major movement any time soon, hold.

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates through three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON’S brand name; oral care products under the LISTERINE brand name; skin care products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON’S Adult, LE PETITE MARSEILLAIS, LUBRIDERM, NEUTROGENA, and RoC brand names; women’s health products, such as sanitary pads under the STAYFREE and CAREFREE, and o.b. tampon brand names; wound care products, including adhesive bandages under the BAND-AID brand name and first aid products under the NEOSPORIN brand name. This segment also provides over-the-counter medicines, including acetaminophen products under the TYLENOL brand name; cold, flu, and allergy products under the SUDAFED brand name; allergy products under the BENADRYL and ZYRTEC brand names; ibuprofen products under the MOTRIN IB brand name; and heartburn products under the PEPCID brand name. The Pharmaceutical segment provides various products in the areas of immunology, infectious diseases and vaccines, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment offers orthopaedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular disease; sterilization and disinfection products to reduce surgical infection; blood glucose monitoring and insulin delivery products; and disposable contact lenses. The company offers its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use, as well as for use in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.

 

Stocks In Action: Gilead Sciences Inc. (GILD), Macy’s, Inc. (M), Medtronic plc (MDT)

Gilead Sciences Inc. (GILD) traded within a range of $74.87 to $75.55 after opening the day at $75.47. The company has seen its stock decrease in value by -24.21% so far this year. The stock was up close to 0.19% on light volume in last trading session and closed at $75.44 per share. After the recent gain, the stock is currently holding -29.1% below its 52 week high of $108.63 and 5.67% above its 12-month low of $71.39. The shares are down by over -4.86% in the last three months, and the RSI indicator value of 49.23 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company’s products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.

Macy’s, Inc. (M) failed to extend gains with the stock declining -1.71% or $-0.77 to close the day at $44.14 on light trading volume of 3.06M shares, compared to its three month average trading volume of 6.25M. The Cincinnati Ohio 45202 based company has been outperforming the department stores group over the past 52 weeks, with the stock gaining 13.75%, compared to the industry which has advanced 9.62% over the same period. With RSI of 77.64, the stock should still continue to rise and get closer to its one year target estimate of $42.15, making it a hold for now.

Macy’s, Inc., together with its subsidiaries, operates stores, Websites, and mobile applications in the United States. Its stores and Websites sell a range of merchandise, including apparel and accessories for men, women, and children; cosmetics; home furnishings; and other consumer goods. The company also operates stores that offer a range of women’s, men’s, and children’s apparel; shoes; fashion accessories; housewares; home textiles; intimate apparel; and jewelry. As of November 14, 2016, it operated approximately 870 stores under the Macy’s, Bloomingdales, Bluemercury, Bloomingdale’s Outlet, and Macy’s Backstage brands, as well as Websites, including macys.com, bloomingdales.com, and bluemercury.com. In addition, it operates as a beauty products and spa retailer. The company was formerly known as Federated Department Stores, Inc. and changed its name to Macy’s, Inc. in June 2007. Macy’s, Inc. was founded in 1830 and is based in Cincinnati, Ohio.

Medtronic plc (MDT) dropped $-0.26 to close the day at a new closing price of $75.52, a -0.34% decrease in value from its previous closing price that moved the stock 7.39% above its 52 week low of $71.03. A total of 3.05M shares exchanged hands during the day compared with its three month average trading volume of 5.33M. The stock, which fluctuated between $75.08 and $76.44 during the day, currently situated -15.4% below its 52 week high. The stock is down by -6.9% in the past one month and down by -12.79% over the past three months. With a one year target estimate of $92 and RSI of 33.32, the stock still has upside potential, making it a hold for now.

Medtronic plc manufactures and sells device-based medical therapies worldwide. The company’s Cardiac and Vascular Group segment offers pacemakers, implantable cardioverter defibrillators and cardiac resynchronization therapy devices, AF products, diagnostics and monitoring devices, and remote monitoring and patient-centered software; and heart valves, percutaneous coronary intervention stent products, surgical valve replacement and repair products, endovascular stent grafts, peripheral vascular intervention products, and products to treat superficial and deep venous diseases. Its Minimally Invasive Therapies Group segment provides gastrointestinal diagnostics, ablation, and interventional lung solutions; stapling, vessel sealing, and other surgical instruments; sutures; electrosurgery products; hernia mechanical devices; mesh implants; products for patient monitoring and recovery; sensors; monitors; compression and dialysis, enteral feeding, and wound care products; and operating room supplies, electrodes, needles, syringes, and sharps disposals. The company’s Restorative Therapies Group segment offers products for various areas of the spine; bone graft substitutes; biologic products; trauma, implantable neurostimulation therapies, and drug delivery systems for the treatment of chronic pain, movement disorders, obsessive-compulsive disorder, overactive bladder, urinary retention, fecal incontinence, and gastroparesis; products to treat conditions of the ear, nose, throat, and neurological disorders; systems that incorporate advanced energy surgical instruments; products for haemostatic sealing of soft tissue and bone; and image-guided surgery and intra-operative imaging systems. Its Diabetes Group segment provides insulin pumps and consumables; continuous glucose monitoring systems; and Web-based therapy management software solutions. It serves hospitals, physicians, clinicians, and patients. Medtronic plc was founded in 1949 and is headquartered in Dublin, Ireland.

 

Stocks Trending Alert: Gilead Sciences Inc. (GILD), Tyson Foods, Inc. (TSN), Rite Aid Corporation (RAD)

Gilead Sciences Inc. (GILD) saw its value increase by 1.13% as the stock gained $0.84 to finish the day at a closing price of $75.3. The stock was lighter in trading and has fluctuated between $71.39-$108.63 per share for the past year. The shares are down by -5.4% in the past three months and down by -10.68% over the past six months. It is currently trading 0.47% above its 20 day moving average and -1.04% below its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $96.19 a share over the next twelve months. The current relative strength index (RSI) reading is 48.67.The technical indicator lead us to believe there will be no major movement any time soon, hold.

Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company’s products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.

Tyson Foods, Inc. (TSN) shares were down in last trading by -0.51% to $58.66. It experienced higher than average volume on day. The stock decreased in value by almost -15.01% over the past week and fell -15.03% in the past month. It is currently trading -17.23% below its 50 day moving average and -14.18% below its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -23.87% decrease in value from its one year high of $77.05. The RSI indicator value of 28.36, lead us to believe that it may correct downwards in the near term.

Tyson Foods, Inc., together with its subsidiaries, operates as a food company worldwide. It operates through four segments: Chicken, Beef, Pork, and Prepared Foods. The company raises and processes chickens into fresh, frozen, and value-added chicken products; processes live fed cattle and live market hogs; and fabricates dressed beef and pork carcasses into primal and sub-primal meat cuts, as well as case ready beef and pork, and fully-cooked meats. It also supplies poultry breeding stock; sells allied products, such as hide and meats; and manufactures and markets frozen and refrigerated food products, including pepperoni, bacon, breakfast sausage, turkey, lunchmeat, hot dogs, pizza crusts and toppings, flour and corn tortilla products, desserts, appetizers, snacks, prepared meals, ethnic foods, soups, sauces, side dishes, meat dishes, breadsticks, and processed meats. Tyson Foods, Inc. offers its products primarily under the Tyson, Jimmy Dean, Hillshire Farm, Ball Park, Van’s, Sara Lee, Chef Pierre, Ball Park, Wright, Aidells, State Fair, Gallo Salame, and Golden Island brands. The company sells its products through its sales staff to grocery retailers, grocery wholesalers, meat distributors, warehouse club stores, military commissaries, industrial food processing companies, chain restaurants or their distributors, live markets, international export companies, and domestic distributors, as well as through independent brokers and trading companies. Tyson Foods, Inc. was founded in 1935 and is headquartered in Springdale, Arkansas.

Rite Aid Corporation (RAD) traded within a range of $7.65 to $7.82 after opening the day at $7.66. The company has seen its stock decrease in value by -0.51% so far this year. The stock was up close to 1.96% on light volume in last trading session and closed at $7.8 per share. After the recent gain, the stock is currently holding -6.02% below its 52 week high of $8.3 and 23.22% above its 12-month low of $6.33. The shares are up by over 4.42% in the last three months, and the RSI indicator value of 62.36 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Rite Aid Corporation, through its subsidiaries, operates a chain of retail drugstores in the United States. The company operates through two segments, Retail Pharmacy and Pharmacy Services. The Retail Pharmacy Segment sells prescription drugs; and a range of other merchandises, such as over-the-counter medications, health and beauty aids, personal care items, cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, and other everyday and convenience products. It also operates retail clinics that provide treatment for common conditions; and a range of preventive services, including screenings, medical tests, immunizations, and basic physical exams. In addition, this segment provides health coaching, shared decision making tools, and health care analytics, including health coaching for medical decisions, chronic conditions, and wellness; population analytic solutions; and consulting services. The Pharmacy Services Segment provides pharmacy benefit management (PBM) services and a range of pharmacy-related services. It also offers integrated mail-order and specialty pharmacy services; and performs prescription adjudication services for other PBMs. Rite Aid Corporation has a strategic alliance with GNC. As of February 27, 2016, the company operated approximately 4,561 stores in 31 states of the United States and in the District of Columbia. Rite Aid Corporation was founded in 1927 and is headquartered in Camp Hill, Pennsylvania.

 

Stocks Trending Alert: Gilead Sciences Inc. (GILD), Tyson Foods, Inc. (TSN), Rite Aid Corporation (RAD)

Gilead Sciences Inc. (GILD) saw its value increase by 1.13% as the stock gained $0.84 to finish the day at a closing price of $75.3. The stock was lighter in trading and has fluctuated between $71.39-$108.63 per share for the past year. The shares, which traded within a range of $73.76 to $75.35 during the day, are down by -5.4% in the past three months and down by -10.68% over the past six months. It is currently trading 0.47% above its 20 day moving average and -1.04% below its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $96.19 a share over the next twelve months. The current relative strength index (RSI) reading is 48.67.The technical indicator lead us to believe there will be no major movement any time soon, hold.

Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company’s products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.

Tyson Foods, Inc. (TSN) shares were down in last trading by -0.51% to $58.66. It experienced higher than average volume on day. The stock decreased in value by almost -15.01% over the past week and fell -15.03% in the past month. It is currently trading -17.23% below its 50 day moving average and -14.18% below its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -23.87% decrease in value from its one year high of $77.05. The RSI indicator value of 28.36, lead us to believe that it may correct downwards in the near term.

Tyson Foods, Inc., together with its subsidiaries, operates as a food company worldwide. It operates through four segments: Chicken, Beef, Pork, and Prepared Foods. The company raises and processes chickens into fresh, frozen, and value-added chicken products; processes live fed cattle and live market hogs; and fabricates dressed beef and pork carcasses into primal and sub-primal meat cuts, as well as case ready beef and pork, and fully-cooked meats. It also supplies poultry breeding stock; sells allied products, such as hide and meats; and manufactures and markets frozen and refrigerated food products, including pepperoni, bacon, breakfast sausage, turkey, lunchmeat, hot dogs, pizza crusts and toppings, flour and corn tortilla products, desserts, appetizers, snacks, prepared meals, ethnic foods, soups, sauces, side dishes, meat dishes, breadsticks, and processed meats. Tyson Foods, Inc. offers its products primarily under the Tyson, Jimmy Dean, Hillshire Farm, Ball Park, Van’s, Sara Lee, Chef Pierre, Ball Park, Wright, Aidells, State Fair, Gallo Salame, and Golden Island brands. The company sells its products through its sales staff to grocery retailers, grocery wholesalers, meat distributors, warehouse club stores, military commissaries, industrial food processing companies, chain restaurants or their distributors, live markets, international export companies, and domestic distributors, as well as through independent brokers and trading companies. Tyson Foods, Inc. was founded in 1935 and is headquartered in Springdale, Arkansas.

Rite Aid Corporation (RAD) traded within a range of $7.65 to $7.82 after opening the day at $7.66. The company has seen its stock decrease in value by -0.51% so far this year. The stock was up close to 1.96% on light volume in last trading session and closed at $7.8 per share. After the recent gain, the stock is currently holding -6.02% below its 52 week high of $8.3 and 23.22% above its 12-month low of $6.33. The shares are up by over 4.42% in the last three months, and the RSI indicator value of 62.36 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Rite Aid Corporation, through its subsidiaries, operates a chain of retail drugstores in the United States. The company operates through two segments, Retail Pharmacy and Pharmacy Services. The Retail Pharmacy Segment sells prescription drugs; and a range of other merchandises, such as over-the-counter medications, health and beauty aids, personal care items, cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, and other everyday and convenience products. It also operates retail clinics that provide treatment for common conditions; and a range of preventive services, including screenings, medical tests, immunizations, and basic physical exams. In addition, this segment provides health coaching, shared decision making tools, and health care analytics, including health coaching for medical decisions, chronic conditions, and wellness; population analytic solutions; and consulting services. The Pharmacy Services Segment provides pharmacy benefit management (PBM) services and a range of pharmacy-related services. It also offers integrated mail-order and specialty pharmacy services; and performs prescription adjudication services for other PBMs. Rite Aid Corporation has a strategic alliance with GNC. As of February 27, 2016, the company operated approximately 4,561 stores in 31 states of the United States and in the District of Columbia. Rite Aid Corporation was founded in 1927 and is headquartered in Camp Hill, Pennsylvania.

 

Stocks Trend Analysis: Opexa Therapeutics, Inc. (OPXA) American Eagle Outfitters, Inc. (AEO) Gilead Sciences Inc. (GILD)

Opexa Therapeutics, Inc. (OPXA) failed to extend gains with the stock declining -28.57% or $-0.42 to close the day at $1.05 on active trading volume of 6.11M shares, compared to its three month average trading volume of 596.99K. The The Woodlands Texas 77381 based company has been underperforming the biotechnology group over the past 52 weeks, with the stock losing -69.57%, compared to the industry which has dropped -2.58% over the same period. With RSI of 41.86, the stock should still continue to rise and get closer to its one year target estimate of $7.67, making it a hold for now.

Opexa Therapeutics, Inc., a biopharmaceutical company, develops personalized immunotherapy to treat multiple sclerosis (MS) and other autoimmune diseases based on its proprietary T-cell technology. The company’s lead product candidate is Tcelna, a novel T-cell immunotherapy, which is in Phase IIb clinical development for the treatment of patients with secondary progressive MS. It is also developing OPX-212 as an autologous T-cell immunotherapy that is in preclinical development to treat neuromyelitis optica. The company was formerly known as PharmaFrontiers Corp. and changed its name to Opexa Therapeutics, Inc. in June 2006. Opexa Therapeutics, Inc. was founded in 2003 and is based in The Woodlands, Texas.

American Eagle Outfitters, Inc. (AEO) grew with the stock adding 4.32% or $0.78 to close at $18.82 on active trading volume of 6.09M compared its three months average trading volume of 4.52M. The Pittsburgh Pennsylvania 15203 based company operating under the Apparel Stores industry has been trending up for the last 52 weeks, with the shares price now 21.19% up for the period and up by 24.26% so far this year. With price target of $19.91 and a 50.7% rebound from 52-week low, American Eagle Outfitters, Inc. has plenty of upside potential, making it a hold with a view buy.

American Eagle Outfitters, Inc. operates as a specialty retailer offering on-trend clothing, accessories, and personal care products under the American Eagle Outfitters and Aerie brands. The company provides denim, bottoms, and other apparel, as well as footwear and accessories for men and women; and intimates, including bras, undies, swim, and other products, as well as apparel and personal care products for women. In addition, it offers sports apparel under the Tailgate brand; and menswear products under the Todd Snyder New York brand name. The company operates approximately 1,000 stores in the United States, Canada, Mexico, China, Hong Kong, and the United Kingdom, and ships to 81 countries through its websites. It also offers its merchandise at 151 stores operated by licensees in 22 countries, as well as through its Websites at ae.com, aerie.com, TailgateClothing.com, and ToddSnyder.com. American Eagle Outfitters, Inc. was founded in 1977 and is headquartered in Pittsburgh, Pennsylvania.

Gilead Sciences Inc. (GILD) failed to extend gains with the stock declining -0.69% or $-0.52 to close the day at $74.46 on lower than average trading volume of 6.02M shares, compared to its three month average trading volume of 9.89M. The Foster City California 94404 based company has been underperforming the biotechnology companies by -6.9138% for last three months and its recent losses have pulled the stock down -25.19% YTD, versus the biotechnology industry which is up 0.06% for the same period. The RSI of 44 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company’s products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.

 

Stocks Under Consideration: Fitbit Inc. (FIT), Gilead Sciences Inc. (GILD), Yahoo! Inc. (YHOO)

Fitbit Inc. (FIT) retreated with the stock falling -0.79% or $-0.07 to close at $8.75 on light trading volume of 8.19M compared its three months average trading volume of 9.6M. The San Francisco California 94105 based company operating under the Scientific & Technical Instruments industry has been trending down for the last 52 weeks, with the shares price now -69.84% down for the period and down by -70.43% so far this year. With price target of $11.44 and a 5.11% rebound from 52-week low, Fitbit Inc. has plenty of upside potential, making it a hold with a view buy.

Fitbit, Inc. provides wearable health and fitness tracking devices. It offers various products, including Fitbit Zip, an entry-level wireless tracker that allows users to track daily activity statistics, such as steps, distance, calories burned, and active minutes; Fitbit One, a clippable wireless tracker, which tracks floors climbed and sleep, as well as daily steps, distance, calories burned, and active minutes; Fitbit Flex, a wristband-style tracker that tracks steps, distance, calories burned, active minutes, and sleep; and Fitbit Charge, an activity and sleep wristband, which tracks steps, distance, calories burned, active minutes, floors climbed, and sleep. The company also provides Fitbit Alta, a customizable wristband that offers call, text, and calendar notifications when paired with the user’s phone and SmartTrack automatic exercise recognition; and Fitbit Charge HR, a wireless heart rate and activity wristband. In addition, it offers Fitbit Blaze, a smart fitness watch that provides multi-sport functionality, tracks outdoor cycling activity, and provides run cues; Fitbit Surge, a fitness watch that features a GPS watch, heart rate tracker, activity tracker, and smartwatch; Aria, a Wi-Fi connected scale that tracks weight, body fat percentage, and body mass index; and Fitbit accessories that include bands and frames for Fitbit Blaze, bands for Fitbit Alta, colored bands for Fitbit Flex, colored clips for Fitbit One and Fitbit Zip, device charging cables, wireless sync dongles, band clasps, sleep bands, and Fitbit apparel. The company offers its products through consumer electronics and specialty retailers, e-Commerce retailers, sporting goods and outdoors retailers, and wireless carriers; and corporate wellness channels, as well as directly worldwide. The company was formerly known as Healthy Metrics Research, Inc. and changed its name to Fitbit, Inc. in October 2007. Fitbit, Inc. was founded in 2007 and is headquartered in San Francisco, California.

Gilead Sciences Inc. (GILD) had a light trading with around 8.17M shares changing hands compared to its three month average trading volume of 9.93M. The stock traded  at the price of $74.62 with -1.27% change on the day. The Foster City California 94404 based company is currently trading 4.52% above its 52 week low of $71.39 and -29.87% below its 52 week high of $108.63. Both the RSI indicator and target price of  and $96.19 respectively, lead us to believe that it could rise over the coming weeks.

Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company’s products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.

Yahoo! Inc. (YHOO) saw its value decrease by -0.63% as the stock dropped $-0.26 to finish the day at a closing price of $41.19. The stock was lighter in trading and has fluctuated between $26.15-$44.92 per share for the past year. The shares are down by -3.13% in the past three months and up by 12.36% over the past six months. It is currently trading 0.09% above its 20 day moving average and -2.54% below its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $45.46 a share over the next twelve months. The current relative strength index (RSI) reading is 48.05.The technical indicator lead us to believe there will be no major movement any time soon, hold.

Yahoo! Inc., together with its subsidiaries, provides search and display advertising services on Yahoo properties and affiliate sites worldwide. The company offers Yahoo Search that serves as a guide for users to discover information on the Internet; Yahoo Mail, which connects users to the people and content; and Yahoo Messenger, an instant messaging service, which enables users to connect, communicate, and share experiences in real-time. It also provides digital content products, including Yahoo News, which gives users to discover, consume, and engage around the news, content, and video; Yahoo Sports, which serves audiences of sports enthusiasts; Yahoo Finance that offers a range of financial data, information, and tools; Yahoo Lifestyle to engage users passionate about style and fashion; and Tumblr, which provides a Web platform and mobile applications on iOS and android to create, share, and curate content, as well as Tumblr messaging that enables users to engage with other users that share their same interests and passions. In addition, the company provides advertiser products, such as Yahoo Gemini, a marketplace for search and native advertising; and BrightRoll, which offers a suite of media-agnostic tools to enable advertisers, publishers, and partners connect with users across ad formats and devices. Further, it offers advertising formats; and digital advertising products, such as Yahoo native, Yahoo video, Yahoo premium, and Yahoo audience ads. Additionally, the company offers Yahoo Mobile Developer suite consisting of Flurry Analytics, Yahoo App Publishing, Yahoo App Marketing, and Tumblr In-App Sharing tools to measure, monetize, advertise, and improve their apps. Yahoo! Inc. was founded in 1994 and is headquartered in Sunnyvale, California.